Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 7:15:939-943.
doi: 10.2147/PPA.S291485. eCollection 2021.

Concordance Between Persons with Multiple Sclerosis and Treating Physician on Medication Effects and Health Status

Efrat Neter  1 , Lea Glass-Marmor  2 , Loren Haiien  2 , Ariel Miller  2   3
Affiliations

Concordance Between Persons with Multiple Sclerosis and Treating Physician on Medication Effects and Health Status

Efrat Neter et al. Patient Prefer Adherence. .

Abstract

Background: As the number of treatment options for multiple sclerosis (MS) has expanded, alignment between physician and patient on effects of medication has emerged as important for medication persistence/discontinuation.

Objective: To evaluate physician-patient agreement levels on medication effect and health status.

Methods: Persons with MS (PwMS) (n=71) participated in a cross-sectional study collecting their satisfaction (using the Treatment Satisfaction Questionnaire for Medication), intention to dis/continue treatment and global health perception; physicians assessed response to medication and global health status.

Results: Concordance between PwMS' assessment of medication effectiveness and physician's assessment on response to medication, health status and EDSS were r s= 0.50, r s= 0.57 and r s= -0.58, respectively.

Conclusion: The significant concordance attests to physician-patient effective communication and may contribute to improved medication adherence.

Keywords: concordance; disease-modifying therapy; multiple sclerosis; participatory medicine; patient-centered approach; patient-reported outcomes.

PubMed Disclaimer

Conflict of interest statement

Dr. Miller has served on the scientific advisory board, and received personal compensation for consulting and/or speaking activities and/or honoraria and/or received grant support for research from: Avanir Pharmaceuticals; Bayer-Schering Pharma; Biogen Idec; Mapi Pharma; Medison Pharma Ltd.; Merck Serono; Novartis; Sanofi-Genzyme; and Teva Pharmaceutical Industries Ltd. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

References

    1. Yeandle D, Rieckmann P, Giovannoni G, Alexandri N, Langdon D. Patient power revolution in multiple sclerosis: navigating the new frontier. Neurol Ther. 2018;7(2):179–187. doi:10.1007/s40120-018-0118-8 - DOI - PMC - PubMed
    1. Kasper J, Köpke S, Mühlhauser I, Nübling M, Heesen C. Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial. Eur J Neurol. 2008;15(12):1345–1352. doi:10.1111/j.1468-1331.2008.02313.x - DOI - PubMed
    1. Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. Mult Scler. 2017;23(2):185–190. doi:10.1177/1352458516671204 - DOI - PubMed
    1. Poulos C, Wakeford C, Kinter E, Mange B, Schenk T. Patient and physician preferences for multiple sclerosis treatments in Germany: a discrete-choice experiment study. Mult Scler J Exp Transl Clin. 2020;6(1):1–14. doi:10.1177/2055217320910778 - DOI - PMC - PubMed
    1. Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Prim. 2018;4(1):1–27. doi:10.1038/s41572-018-0041-4 - DOI - PubMed